Interestingly, the upregulation of the PPAR/PGC1α pathway was only observed in adipose tissues, not in the liver (Figure S2); however, GTB1TM-treated mice showed improvements in HFD-induced hepatomegaly, hepatic steatosis represented by TG level (Figure 2E,G,H), and circulating lipid profiles (Figure 3). The gene discussed is PPARGC1A; the disease is fatty liver disease.